Journal of Developmental Medicine(Electronic Version)   2014, Vol. 2   Issue (3): 150-154    DOI:  | 
										 
				   
				
					
						
							
								
									 | 
									
										
		  							 | 
          							
		  									  								 
		  									  							|
		  									  								 
		  									  							 | 
        						 
      						 
      					 | 
  					 
  					
    					 | 
   					 
   										
    					| Clinical analysis of haplotype allogeneic hematopoietic stem cell transplantation for juvenile myelomonocytic leukemia | 
  					 
  					  										
						| GUO Zhi, CHEN Hui-ren, LIU Xiao-dong, et al
 | 
					 
															
						| Department of Hematology, General Hospital, Beijing Military Area,Beijing 100700, China | 
					 
										
						 | 
					 
				 
				
				
					
						
							
								
									
										
											
                        					 
												
													
													    | 
													    	
														 | 
													 
																										
													
														
															
													
													    
													     		                            						                            																	    Abstract  【Abstract】 Objective The study was aimed to explore the efficacy and safety of haplotype allogeneic hematopoietic stem cell transplantation (allo-HSCT)in treatment of juvenile myelomonocytic leukemia(JMML). Method From January 2011 to January 2014, six children with JMML receiving haploidentical allo-HSCT were included in the study, including 4 males and 2 females, aged from 4 to 12 years old, and the mean age was 5.6 years. The median time from diagnosis to transplantation was 6.5 months (2 to 25 months).Donors received granulocyte colony-stimulating factor mobilization. Stem cell transplantation was collectedfrom both peripheral blood and bone marrow. CTX+FLU+ATG program was used as conditioning regimen, and combined immunosuppressive agents were used for graft-versus-host disease (GVHD) prophylaxis, including cyclosporine A, amethopterin, tacrolimus,etc. Toxic and side effects,incidence of GVHD and disease-free survival of these children after transplantation were observed. Result All patients reached hematopoietic reconstitution. The average time was 16.5 d and 18.2 d, respectively, with neutrophils ≥ 0.5×109/L and platelets ≥ 20×109/L. Implantation was confirmed by the evidence of 100% of donor hematopoiesis.With a median follow-up duration of 21.5 months (2 - 40 months), three cases developed acute GVHD, 
two cases showed chronic GVHD. One case died of GVHD, one died of relapse, and the remaining 4 patients remained disease-free survival. The disease-free survival rate was 66.7%. Conclusion Haploidentical hematopoietic stem cell transplantation could be chosen as a treatment method for patients with JMML in the absence of matched donors.
																										     | 
														 
														
														
															| 
															    																	Received: 04 May 2014
																	    
															    															    															    																	Published: 05 September 2019
															    															 | 
														 
														 																											    																														 
															 | 
																															
															
													    	
															 | 
																
															
														 
														
													 
													
												 
												
												
												
													
														
															
																
																																																																
																	| No related articles found! | 
																 
																															 
														 | 
													 
												 
											 
											
											 
											
											 
										 
									 | 
								 
							 
						 | 
					 
				 
			
		 |